Literature DB >> 9131485

The human drug metabolizing cytochromes P450.

S A Wrighton1, M VandenBranden, B J Ring.   

Abstract

The superfamily of heme-thiolate proteins known as the cytochromes P450 is responsible for the oxidative metabolism of the majority of drugs. Thus, the phenotypes of individuals with respect to their levels of catalytically active cytochromes P450 determines to a large part the substantial interindividual variation observed in the metabolic clearance of drugs. Over the past 10 years 15 different human cytochromes P450 involved in drug metabolism have been isolated and characterized to varying degrees. This brief review discusses the characterization of these cytochromes P450 and how this knowledge has been used by the pharmaceutical industry to aid in the development of new drugs.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 9131485     DOI： 10.1007/bf02353474

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN： 0090-466X


  16 in total

Review 1.  Enzyme induction by drugs and toxins.

Authors:  A M Batt; G Siest; J Magdalou; M M Galteau
Journal:  Clin Chim Acta       Date:  1992-07-31       Impact factor: 3.786

Review 2.  The human hepatic cytochromes P450 involved in drug metabolism.

Authors:  S A Wrighton; J C Stevens
Journal:  Crit Rev Toxicol       Date:  1992       Impact factor: 5.635

3.  CYP2E1 and ALDH2 genotypes and alcohol dependence in Japanese.

Authors:  K Iwahashi; Y Matsuo; H Suwaki; K Nakamura; Y Ichikawa
Journal:  Alcohol Clin Exp Res       Date:  1995-06       Impact factor: 3.455

Review 4.  In vitro methods for assessing human hepatic drug metabolism: their use in drug development.

Authors:  S A Wrighton; M Vandenbranden; J C Stevens; L A Shipley; B J Ring; A E Rettie; J R Cashman
Journal:  Drug Metab Rev       Date:  1993       Impact factor: 4.518

Review 5.  Clinical implications of genetic polymorphism in drug metabolism.

Authors:  G T Tucker
Journal:  J Pharm Pharmacol       Date:  1994-05       Impact factor: 3.765

6.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.

Authors:  T Shimada; H Yamazaki; M Mimura; Y Inui; F P Guengerich
Journal:  J Pharmacol Exp Ther       Date:  1994-07       Impact factor: 4.030

7.  Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8.

Authors:  A Rahman; K R Korzekwa; J Grogan; F J Gonzalez; J W Harris
Journal:  Cancer Res       Date:  1994-11-01       Impact factor: 12.701

8.  Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities.

Authors:  M V Relling; J S Lin; G D Ayers; W E Evans
Journal:  Clin Pharmacol Ther       Date:  1992-12       Impact factor: 6.875

9.  A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles.

Authors:  P Fernandez-Salguero; S M Hoffman; S Cholerton; H Mohrenweiser; H Raunio; A Rautio; O Pelkonen; J D Huang; W E Evans; J R Idle
Journal:  Am J Hum Genet       Date:  1995-09       Impact factor: 11.025

10.  In vitro metabolism of zatosetron. Interspecies comparison and role of CYP 3A.

Authors:  B J Ring; C J Parli; M C George; S A Wrighton
Journal:  Drug Metab Dispos       Date:  1994 May-Jun       Impact factor: 3.922
View more
  31 in total

Review 1.  Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans.

Authors:  G R Wilkinson
Journal:  J Pharmacokinet Biopharm       Date:  1996-10

2.  Intrinsic sexually dimorphic expression of the principal human CYP3A4 correlated with suboptimal activation of GH/glucocorticoid-dependent transcriptional pathways in men.

Authors:  Chellappagounder Thangavel; Ettickan Boopathi; Bernard H Shapiro
Journal:  Endocrinology       Date:  2011-09-27       Impact factor: 4.736

Review 3.  The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein.

Authors:  Y Zhang; L Z Benet
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

4.  Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract.

Authors:  Mari Thörn; Niklas Finnström; Stefan Lundgren; Anders Rane; Lars Lööf
Journal:  Br J Clin Pharmacol       Date:  2005-07       Impact factor: 4.335

Review 5.  Cytochrome P450 3A: ontogeny and drug disposition.

Authors:  S N de Wildt; G L Kearns; J S Leeder; J N van den Anker
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

6.  Potentially increasing the metabolic stability of drug candidates via computational site of metabolism prediction by CYP2C9: The utility of incorporating protein flexibility via an ensemble of structures.

Authors:  Matthew L Danielson; Prashant V Desai; Michael A Mohutsky; Steven A Wrighton; Markus A Lill
Journal:  Eur J Med Chem       Date:  2011-06-23       Impact factor: 6.514

Review 7.  Clinically significant drug interactions with antidepressants in the elderly.

Authors:  Edoardo Spina; Maria Gabriella Scordo
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

8.  Identification of polymorphisms in the 3'-untranslated region of the human pregnane X receptor (PXR) gene associated with variability in cytochrome P450 3A (CYP3A) metabolism.

Authors:  L Oleson; L L von Moltke; D J Greenblatt; M H Court
Journal:  Xenobiotica       Date:  2010-02       Impact factor: 1.908

Review 9.  Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

10.  Gene expression of cytochromes P450 in liver transplants over time.

Authors:  Mari Thörn; Stefan Lundgren; Gustaf Herlenius; Bo-Göran Ericzon; Lars Lööf; Anders Rane
Journal:  Eur J Clin Pharmacol       Date:  2004-06-10       Impact factor: 2.953
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.